On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
The team that advised Excellergy on the transaction includes:
Mergers & Acquisitions
Robert Ishii
Ross Tanaka
Ryan Cooper
Robert Gunn
Matthew Fleming
Corporate
Jennifer Knapp
Jacob Morales
Technology Transactions
Lowell Segal
Kexi Wang
Rachel Slyker
Isaiah Loya
Gopika Mesrobian
Patents and Innovations
Maya Skubatch
Rex Watkins
FDA Regulatory
Eva Yin
Antitrust and Competition
Maureen Ohlhausen
Michelle Yost Hale
Deirdre Carroll
Kimberley Biagioli
Knychelle Passmore
Employee Benefits and Competition
Megan Schilling
Jason Chan
Laura Yun
Employment and Trade Secrets
Matt Gorman
Chimene Cooper
Data, Privacy, and Cybersecurity
Matthew Staples
Michael O’Brien
Kimia Favagehi
National Security
Stephen Heifetz
Seth Cowell
Anne Seymour
Nimit Dhir
Waqas Shahid
Real Estate
James McCann
Martin Sul
Alex Corluyan
For more information, please see Excellergy’s news release. Additional coverage can be found on Bloomberg and The Wall Street Journal.